AngioDynamics, Inc. (NASDAQ:ANGO) Shares Bought by Marshall Wace LLP

Marshall Wace LLP increased its position in shares of AngioDynamics, Inc. (NASDAQ:ANGO - Free Report) by 1,335.1% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 476,824 shares of the medical instruments supplier's stock after purchasing an additional 443,598 shares during the quarter. Marshall Wace LLP owned 1.18% of AngioDynamics worth $4,368,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently modified their holdings of the company. SBI Securities Co. Ltd. acquired a new position in AngioDynamics in the fourth quarter valued at approximately $28,000. R Squared Ltd acquired a new position in AngioDynamics in the fourth quarter valued at approximately $49,000. US Bancorp DE lifted its holdings in AngioDynamics by 1,938.0% in the fourth quarter. US Bancorp DE now owns 6,705 shares of the medical instruments supplier's stock valued at $61,000 after acquiring an additional 6,376 shares during the period. Quinn Opportunity Partners LLC acquired a new position in AngioDynamics in the fourth quarter valued at approximately $92,000. Finally, SG Americas Securities LLC lifted its holdings in AngioDynamics by 21.3% in the fourth quarter. SG Americas Securities LLC now owns 16,102 shares of the medical instruments supplier's stock valued at $147,000 after acquiring an additional 2,832 shares during the period. Institutional investors and hedge funds own 89.43% of the company's stock.

AngioDynamics Stock Down 3.0 %

Shares of AngioDynamics stock traded down $0.29 on Wednesday, reaching $9.29. The company's stock had a trading volume of 382,949 shares, compared to its average volume of 558,755. The company has a market capitalization of $377.24 million, a P/E ratio of -1.65 and a beta of 0.52. AngioDynamics, Inc. has a 52-week low of $5.47 and a 52-week high of $13.50. The stock has a 50-day moving average price of $9.50 and a 200-day moving average price of $9.18.

AngioDynamics (NASDAQ:ANGO - Get Free Report) last issued its quarterly earnings results on Wednesday, April 2nd. The medical instruments supplier reported $0.03 EPS for the quarter, topping the consensus estimate of ($0.13) by $0.16. AngioDynamics had a negative return on equity of 7.26% and a negative net margin of 79.38%. The firm had revenue of $72.00 million during the quarter, compared to analysts' expectations of $70.30 million. The firm's revenue was down 4.3% compared to the same quarter last year. Sell-side analysts forecast that AngioDynamics, Inc. will post -0.37 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Separately, HC Wainwright reissued a "buy" rating and issued a $16.00 price target (up from $15.00) on shares of AngioDynamics in a report on Monday, April 7th.

About AngioDynamics

AngioDynamics, Inc, a medical technology company, engages in the design, manufacture, and sale of medical, surgical, and diagnostic devices for the use in treating peripheral vascular disease, and oncology and surgical settings in the United States and internationally. The company offers Auryon Atherectomy system that is designed to deliver an optimized wavelength, pulse width, and amplitude to remove lesions while preserving vessel wall endothelium.